Scott Thorogood is a serial CEO and entrepreneur with over 25 years of international senior management and turnaround experience, focused on life sciences, software, cybersecurity, and other technology initiatives. He is the co-founding chairman and CEO of Nanovision Biosciences in La Jolla, California. Nanovision has developed a breakthrough nano-scale retinal implant designed to restore sight to individuals blinded by retinal diseases such as macular degeneration. Its non-biological division is applying its image-sensor technology based on a new physics discovery to low light imaging applications for DoD and commercial markets.

In addition to Nanovision, Scott has co-founded several technology companies and served as a board member and executive advisor for many other emerging-growth ventures internationally, including as chairman and founding CEO of Tradebeam (acquired by CDC / Aptean) and Oasis Inc. (acquired by Sybase/SAP), as well as board observer and business advisor for Renova Therapeutics, a transformational biopharmaceutical company focused on a one-time gene therapy treatment for congestive heart failure (CHF) and type 2 diabetes. He also secured the founding investment required to launch the company.

In addition, Scott served as executive business turnaround and technology advisor for the Canopy Group board of directors, a Utah-based venture capital group with a large portfolio of technology companies. He holds a BS in Mathematics and Psychology from the University of Alberta and serves as a virtual entrepreneur in residence for the Johnson Graduate School of Management at Cornell University.